Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.

In light of recent federal research funding cuts, the Arthritis Foundation and CARRA each contributed an additional $100,000 to support the grant program this year. Meanwhile, demand for research ...

The diagnosis of several of them can be aided by blood tests and/or imaging. There may not be a cure, but with lifestyle ...

Senior medical experts have explained why women are more at risk of developing arthritis than men, attributing it to several ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Find out more about lupus: the symptoms, types, causes, and who is at risk for developing this chronic autoimmune disease.

After years of mysterious symptoms and scores of tests by dozens of doctors, she finally saw a rheumatologist who diagnosed her with Sjögrens disease, an autoimmune disorder that is more common than ...

Zentiva Group has entered a licence and supply agreement with Lupin for the commercialisation of latter’s biosimilar Certolizumab Pegol.